Incyte Co. (NASDAQ:INCY) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in Incyte Co. (NASDAQ:INCY) by 262.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,407 shares of the biopharmaceutical company’s stock after acquiring an additional 71,963 shares during the quarter. SG Americas Securities LLC owned 0.05% of Incyte worth $6,866,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in shares of Incyte during the 3rd quarter worth $156,611,000. Mizuho Securities USA LLC raised its stake in Incyte by 13,814.7% in the third quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock valued at $132,207,000 after buying an additional 1,985,726 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its holdings in Incyte by 2,486.8% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 394,646 shares of the biopharmaceutical company’s stock worth $23,923,000 after buying an additional 379,390 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Incyte by 29.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company’s stock worth $106,369,000 after acquiring an additional 364,169 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Incyte by 24.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,181,269 shares of the biopharmaceutical company’s stock worth $71,617,000 after purchasing an additional 230,665 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Activity

In other news, insider Thomas Tray sold 650 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $70.64, for a total value of $45,916.00. Following the completion of the transaction, the insider now owns 23,962 shares of the company’s stock, valued at $1,692,675.68. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 3,680 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $79.68, for a total value of $293,222.40. Following the transaction, the executive vice president now directly owns 58,042 shares in the company, valued at approximately $4,624,786.56. This represents a 5.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,375 shares of company stock worth $1,737,578 over the last three months. 17.60% of the stock is currently owned by corporate insiders.

Incyte Stock Performance

Shares of INCY opened at $72.59 on Friday. The company has a market capitalization of $13.98 billion, a PE ratio of 518.54, a P/E/G ratio of 0.53 and a beta of 0.71. Incyte Co. has a 52-week low of $50.35 and a 52-week high of $83.95. The company has a 50-day simple moving average of $71.76 and a 200-day simple moving average of $68.33. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.12). The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The company’s quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 EPS. Equities research analysts predict that Incyte Co. will post 0.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on INCY shares. BMO Capital Markets reiterated an “underperform” rating and issued a $52.00 price target (up from $48.00) on shares of Incyte in a research note on Wednesday, October 30th. Wolfe Research assumed coverage on shares of Incyte in a research note on Tuesday, October 1st. They set an “outperform” rating and a $84.00 price target on the stock. Citigroup raised their price objective on Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Oppenheimer boosted their target price on Incyte from $81.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, William Blair restated an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.71.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.